An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia

Andreasen N C , Carpenter W T, Jr. , Kane J M , Lasser R A , Marder S R , Weinberger D R (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry162: 441-449

Barnes T R E , McPhillips M A (1998) The role of medication in the re-integration of schizophrenia. In J A Lieberman (ed.), Re-integration of the Schizophrenic Patient. Science Press, London, pp. 21-34.

Chue P (2003) Risperidone long-acting injection. Expert Rev Neurotherapeutics3: 435-446

Ereshefsky L , Mascarenas C A (2003) Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry64Suppl 16: 18-23

Fleischhacker W W , Eerdekens M , Karcher K , Remington G , Llorca P , Chrzanowski W , Martin S , Gefvert O (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry64: 1250-1257

Gefvert O , Eriksson B , Persson P , Helldin L , Bjorner A , Mannaert E , Remmerie B , Eerdekens M , Nyberg S (2005) Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Constatrade mark) in patients with schizophrenia. Int J Neuropsychopharmacol8: 27-36

Kane J (2001) Progress defined-short-term efficacy, long-term effectiveness. Int Clin Psychopharmacol16Suppl 1: S1-S8

Kane J M , Eerdekens M , Lindenmayer J P , Keith S J , Lesem M , Karcher K (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry160: 1125-1132

Leucht S , Barnes T R , Kissling W , Engel R R , Correll C , Kane J M (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry160: 1209-1222

Marder S R (2003) Overview of partial compliance. J Clin Psychiatry64Suppl 16: 3-9

Müller N (2004) Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry37Suppl 2: S141-S147

NICE (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Health Technology Appraisal No. 43. National Institute for Clinical Excellence, London

Ware J E, Jr. , Sherbourne C D (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care30: 473-483